On April 15, 2016 a California district court ordered the Alzheimer's Institute of America to pay Finnegan client Eli Lilly roughly $4.5 million in attorneys' fees after losing a suit related to a patent covering Alzheimer's detection.
The Alzheimer’s Institute of American filed suit against Eli Lilly and Elan Pharmaceuticals in 2010, alleging the pharmaceutical companies infringed two of its patents. In 2011, the suit was stayed, pending the outcome of another trial where Alzheimer’s Institute of America alleged the University of Pennsylvania and Avid Radiopharmaceuticals, Inc. were also infringing the same patents. In 2012, the suit against Eli Lilly and Elan was dismissed, citing judicial estoppel. The judge later granted Eli Lilly and Elan’s motions for attorneys’ fees, finding that the suit was exceptional and attorneys' fees were justified.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.